Oruka Therapeutics: How Extended Half-Lives and Strong Study Data Drive Analysts to Price Targets of $180

Revolutionizing Antibody Therapy through Extended Half-Lives Oruka Therapeutics (ORKA) , an emerging biopharmaceutical company in the clinical development phase, specializes in the development of novel monoclonal antibodies for the treatment of psoriasis and other immune-mediated skin disorders. The core of the company’s strategy lies in optimizing already validated mechanisms of action through state-of-the-art antibody technology. The solutions the company aims to offer patients target to enable significant and lasting symptom relief through...